- Bio-Techne’s 2Q adjusted EPS was 42 cents, beating both last year’s 40 cents and the estimated 39 cents.
- The company reported net sales of $297.0 million, marking a 9% increase year-over-year, surpassing the estimated $285.9 million.
- Protein Sciences division reported net sales of $211.6 million, a 7% increase year-over-year, beating the estimated $202.9 million.
- Diagnostics & Genomics division achieved net sales of $84.1 million, up 12% year-over-year, exceeding the expected $83 million.
- Intersegment revenue was reported at -$0.5 million, a 5% decrease year-over-year, against the estimate of $79,780.
- The company focused on profitability, achieving a 30.1% adjusted operating margin, which is a sequential increase of 110 basis points.
- Market analyst ratings include 11 buy recommendations, 5 hold recommendations, and 0 sell recommendations for Bio-Techne.
Bio Techne Corp on Smartkarma
Analyst coverage of Bio-Techne Corporation on Smartkarma, an independent investment research network, includes insights from Baptista Research. In a report titled “Bio-Techne Corporation: An Insight Into Its Market Position & Product Expansion in Diagnostics and Spatial Biology! – Major Drivers,” Baptista Research highlights the company’s solid performance in the first quarter of Fiscal Year 2025, driven by a 4% year-over-year organic revenue growth. The report examines factors influencing the company’s future stock price and conducts an independent valuation using a Discounted Cash Flow (DCF) methodology.
Another report by Baptista Research, “Bio-Techne Corporation: Enhanced Investment in Molecular Diagnostics,” discusses the company’s earnings call for the fourth quarter of fiscal year 2024. Despite a challenging external environment with reduced biotech funding, Bio-Techne demonstrated strategic execution and achieved a modest 1% year-over-year organic revenue growth. Baptista Research analyzes potential influences on the company’s stock price in the near future and performs a valuation using a DCF methodology.
A look at Bio Techne Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores for Bio Techne Corp, the company shows a moderate overall outlook. With a Value score of 2 and Dividend score of 2, Bio Techne Corp may not be considered a top choice for value and dividend investors. However, the company’s Growth score of 3 reflects positive potential for expansion in the future, indicating opportunities for increasing revenues and market presence. Additionally, both Resilience and Momentum scoring a 3 suggest that Bio Techne Corp has shown stability in weathering market fluctuations and has demonstrated positive performance trends that could attract investors seeking long-term growth.
Specializing in biotechnology products and clinical diagnostic controls, Bio Techne Corp focuses on proteins, cytokines, growth factors, immunoassays, and small molecules. Overall, while the company’s Smartkarma Smart Scores highlight areas for improvement, particularly in Value and Dividend factors, its strengths in Growth, Resilience, and Momentum indicate a promising long-term outlook for investors looking for potential growth opportunities in the biotechnology sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
